Agenus Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2017. Agenus is a clinical-stage immuno-oncology company developing antibody therapies, cancer vaccines and adjuvants. Its programs include partnered antibody candidates and QS-21 adjuvant programs licensed to GSK.
Financial performance
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $3.4 million | $4.4 million | $34.5 million | $17.0 million |
| Research and development expense | $25.8 million | $21.6 million | $84.3 million | $69.0 million |
| General and administrative expense | $8.1 million | $8.1 million | $24.0 million | $24.5 million |
| Operating loss | $31.7 million | $36.2 million | $73.8 million | $87.8 million |
| Net loss | $36.8 million | $40.8 million | $85.7 million | $100.9 million |
| Loss per common share, basic and diluted | $0.37 | $0.47 | $0.88 | $1.16 |
| Cash used in operating activities | Not presented quarterly | Not presented quarterly | $68.4 million | $63.8 million |
Nine-month 2017 revenue included a $20.0 million accelerated Incyte milestone payment and $12.0 million in Incyte development-cost reimbursements. Q3 revenue was primarily collaboration-related, including $2.5 million of Incyte cost reimbursements. The filing does not present gross margins; the company reported substantial operating and net losses.
At September 30, 2017, cash, cash equivalents and short-term investments totaled $70.1 million, down $6.4 million from December 31, 2016. Total current assets were $84.3 million and current liabilities $54.4 million. Balance-sheet debt carrying value was $143.2 million, including $20.0 million current and $123.3 million long-term. The filing reports $114.1 million principal outstanding and $32.1 million accrued non-cash interest. Accumulated deficit was $991.4 million and stockholders’ deficit $51.6 million.
Material changes and notable items
- Nine-month revenue more than doubled year over year, chiefly due to the $20.0 million Incyte milestone and higher collaboration reimbursements. Q3 revenue declined about 24% year over year.
- R&D expense increased 22% for the nine-month period, primarily reflecting antibody-program advancement, increased third-party services and higher personnel costs. G&A declined 2%.
- Nine-month net loss narrowed year over year, partly reflecting a much smaller contingent purchase-price fair-value adjustment than in 2016. Q3 R&D spending increased, while net loss was lower than the prior-year quarter.
- In February, the Incyte agreement converted GITR and OX40 from profit-share to royalty-bearing programs: Incyte funds development and commercialization, and Agenus may receive a 15% royalty on global net sales if products are approved. Agenus received $20.0 million in accelerated milestones and sold Incyte 10 million shares for $60.0 million. Up to $510.0 million in additional potential milestones remains, subject to achievement.
- In March, Agenus extended the maturity of its $14.0 million subordinated notes to February 2020. In October, GSK’s SHINGRIX received U.S. FDA approval and Canadian authorization; the first QS-21-containing product launch was anticipated in 2018.
Liquidity, outlook and risks
Management stated that September-end resources plus an irrevocably elected $15.0 million draw under the existing note agreement were expected to fund operations into the third quarter of 2018, assuming anticipated additional funding from sources including partnering or out-licensing. Despite those plans and potential spending reductions, the company disclosed substantial doubt about its ability to continue as a going concern for the twelve months following issuance. It expects significant future losses and may need additional equity, debt, partnering, asset-sale or other financing; availability and terms are uncertain.
On November 2, 2017, Agenus elected to issue an additional $15.0 million of notes following SHINGRIX approval, with closing expected in December. The notes bear 13.5% interest compounded quarterly and are principally payable from GSK vaccine royalties; insufficient royalties may result in interest capitalization. The company also reported approximately $1.9 million net proceeds from October ATM share sales and an effective shelf registration permitting offerings of up to $250 million, including up to 15 million ATM shares. These financing options may dilute shareholders or increase leverage.
Key risks include continued cash burn and dependence on future financing; early-stage clinical programs and uncertain regulatory outcomes; reliance on Incyte and GSK for development, commercialization and royalties; and debt terms that could pressure liquidity. GSK royalties on shingles and malaria vaccines are pledged to the note purchasers before any residual royalties revert to Agenus. Management also cited foreign-currency exposure, manufacturing and clinical execution risks, and intense competition. No specific financial guidance beyond the conditional cash-runway estimate was provided.
Investor verification priorities
- Confirm the closing, proceeds and resulting debt balance from the additional $15.0 million notes, including how the 13.5% compounded interest affects future obligations.
- Track quarterly cash burn and whether liquidity extends beyond the company’s stated third-quarter 2018 runway; assess the disclosed going-concern uncertainty.
- Verify SHINGRIX launch progress, royalty generation and the extent to which GSK royalties service the notes rather than provide cash to Agenus.
- Monitor Incyte program progress, potential milestone achievement and any eventual royalty-bearing product sales; milestones and royalties are contingent.
- Assess R&D spending, clinical-trial progress and share issuance under the ATM and shelf programs, including dilution.